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Original Article
Aim: The purpose of this study is to investigate the impact of arterial stiffness assessed using Cardio-ankle Vas-
cular Index (CAVI) on long-term outcome after acute coronary syndrome (ACS). 
Methods: A total of 387 consecutive patients (324 males; age, 64±11 years) with ACS were enrolled. We exam-
ined CAVI and brachial-ankle pulse wave velocity (ba PWV) as the parameters of arterial stiffness. The patients 
were divided into two groups according to the cut-off value of CAVI determined using the receiver operating 
characteristic curve for the prediction of major adverse cardiovascular events (MACE): low-CAVI group, 177 
patients with CAVI ＜8.35; high-CAVI group, 210 patients with CAVI ≥ 8.35. The primary endpoint was the 
incidence of MACE (cardiovascular death, recurrence of ACS, heart failure requiring hospitalization, or stroke). 
Results: A total of 62 patients had MACE. Kaplan–Meier analysis demonstrated a significantly higher probabil-
ity of MACE in the high-CAVI group than in the low-CAVI group (median follow-up: 62 months; log-rank, p＜ 
0.001). Multivariate analysis suggested that CAVI was an independent predictor of MACE (hazard ratio [HR], 
1.496; p=0.02) and cardiovascular death (HR, 2.204; p=0.025), but ba PWV was not. We investigated the incre-
mental predictive value of adding CAVI to the GRACE score (GRS), a validated scoring system for risk assess-
ment in ACS. Stratified by CAVI and GRS, a significantly higher rate of MACE was seen in patients with both 
higher CAVI and higher GRS than the other groups (p＜0.001). Furthermore, the addition of CAVI to GRS 
enhanced net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI, 0.337, 
p=0.034; and IDI, 0.028, p=0.004).
Conclusion: CAVI was an independent long-term predictor of MACE, especially cardiovascular death, adding 
incremental clinical significance for risk stratification in patients with ACS.
has attracted attention as a potentially useful parame-
ter for risk stratification of patients with ACS3, 4). Car-
dio-ankle vascular stiffness index (CAVI) is a noninva-
sive measure of arterial stiffness that is not influenced 
by blood pressure at the time of examination5, 6). We 
previously reported that high CAVI was an indepen-
dent predictor of cardiovascular (CV) events and non-
fatal ischemic stroke in patients with ACS3). However, 
Introduction
Acute coronary syndrome (ACS) is one of the 
leading causes of morbidity and mortality in most 
developed countries even in the era of optimal reper-
fusion therapy1, 2). Therefore, proper risk stratification 
is crucial for the assessment of long-term prognosis 
after ACS. Recent studies showed that arterial stiffness 
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plasma glucose value of ≥ 200 mg/dL, or diabetic pat-
tern based on 75-g oral glucose tolerance tests. We 
excluded patients with any of the following character-
istics: (1) persistent atrial fibrillation (n=19), (2) 
severe aortic insufficiency (n=4), (3) peripheral arte-
rial disease (Ankle Brachial index ≤ 0.9 or previous 
history of lower extremity bypass and/or endovascular 
therapy) (n=25), (4) CAVI data not available (n=3), 
or (5) informed consent was not given (n=6). A total 
of 390 patients with ACS met the eligibility criteria 
and were enrolled. Three patients were lost to follow-
up, so we analyzed the cases of 387 patients in the 
current study (Fig.1). All patients underwent calcula-
tion of GRS at admission8), and a high GRS was 
defined as ＞140 based on previous reports7). The 
study protocol was approved by the Yokohama City 
University Medical Center Institutional Review Board, 
and all patients provided written informed consent 
(UMIN-CTR ID: UMIN000016651).
Two-Dimensional Echocardiography 
A standardized complete echocardiographic 
examination was performed at the same phase as 
CAVI measurement by experienced sonographers 
blinded to the clinical data and CAVI following a 
standard protocol11). All images were obtained using a 
commercial ultrasound system (Vivid q or Vivid E9, 
GE Healthcare). The left ventricular ejection fraction 
was calculated using the biplane modified Simpson 
method. The peak early diastolic velocity (E) was 
imaged at the tip of the mitral leaflets from the apical 
four-chamber view. Tissue Doppler imaging was 
applied to the apical four-chamber view to determine 
peak early (é) velocities at the septal mitral valve 
annulus. E/é (septal) was calculated as an index of left 
ventricular diastolic function.
because of relatively short follow-up duration (15 
months), we could not evaluate the effect of CAVI on 
long-term outcomes and CV mortality. 
The Global Registry of Acute Coronary Events 
risk score (GRS) is an established and validated risk 
scoring system recommended by current guidelines7, 8). 
Although the scoring system has a good predictive 
value for adverse CV disease events in ACS, it does 
not include novel risk factors such as arterial stiffness. 
Aim
In this study, we explored the effect of arterial 
stiffness assessed using CAVI on CV events in patients 
with ACS during a long-term period. Furthermore, 
we investigated whether CAVI could improve the 
prognostic performance of the GRS. 
Methods
Study Population
We studied 447 patients with ACS who under-
went early coronary angiography in Yokohama City 
University Medical Center between April 2012 and 
February 2016. ACS was defined as ST-segment eleva-
tion myocardial infarction, non-ST-segment elevation 
myocardial infarction, and unstable angina pectoris 
according to the current guideline7). The presence of 
hypertension was defined as blood pressure ＞140/90 
mm Hg9) or treatment with oral antihypertensive 
drugs. Dyslipidemia was defined as plasma levels of 
fasting triglycerides ≥ 150 mg/dL and/or fasting total 
cholesterol ≥ 200 mg/dL and/or low-density lipopro-
tein cholesterol ≥ 130 mg/dL10). Diabetes mellitus was 
determined using the following criteria: medical his-
tory, fasting glucose value of ≥ 126 mg/dL, casual 
Fig.1. Study protocol flow chart
CAVI indicates cardio-ankle vascular index.
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which is a graphical user interface for R (version 3.1.2, 
The R Foundation for Statistical Computing, Vienna, 
Austria). Continuous variables were expressed as mean 
±standard deviation for normally distributed variables 
and as median (IQR) for skewed distributed variables. 
Differences between the two groups were tested using 
the t-test for normally distributed variables, Mann–
Whitney U test for skewed distributed variables, and 
chi-square test or Fisher exact test as appropriate for 
categorical variables. Receiver operating characteristic 
(ROC) curves were analyzed to assess the cut-off value 
of CAVI for the prediction of MACE. The optimal 
cut-off value was defined as the value that gives the 
maximal sum of sensitivity and specificity. The area 
under the curve (AUC) of CAVI was 0.663, sensitivity 
=0.790, and 1-specificity=0.495. Accordingly, we 
divided the patients into two groups by CAVI=8.35: 
low-CAVI group, 177 patients with CAVI ＜8.35; 
high-CAVI group, 210 patients with CAVI ≥ 8.35. 
We used Cox proportional-hazards models to estimate 
hazard ratios (HR) for endpoints and 95% confidence 
intervals (CI) using univariate and multivariate mod-
els. Coronary risk factors (age, male sex, hypertension, 
body mass index (BMI), current smoker, dyslipidemia, 
diabetes mellitus, and estimated glomerular filtration 
rate (eGFR)), GRS, ba PWV, and CAVI were entered 
in the univariate analysis. Baseline variables that were 
considered clinically relevant were entered into the 
multivariate analysis (forced inclusion model) together 
with CAVI (model 1: age, male sex, current smoker, 
hypertension, dyslipidemia, diabetes mellitus, BMI, 
eGFR, ba PWV and CAVI; model 2: GRS and 
CAVI). GRS was not included in multivariate analysis 
model 1 because of its high covariance with the coro-
nary risk factors. The cumulative incidence of a clini-
cal event was assessed using the Kaplan–Meier method 
and compared using the log-rank test. We evaluated 
whether the combination of CAVI and GRS gives a 
better predictive accuracy for MACE compared with 
each parameter alone. In addition, the incremental 
effect of adding CAVI to GRS to predict future deaths 
and CV events was evaluated using the net reclassifica-
tion index (NRI) as previously described14). As a sensi-
tivity analysis, we used a logistic regression model on 
MACE using the combination of CAVI and GRS as a 
predictor variable. The cumulative incidence for all 





The baseline characteristics of all patients are 
listed in Table 1. Patients in the high-CAVI group 
Measurement of Arterial Stiffness (CAVI and 
Brachial-Ankle Pulse Wave Velocity)
CAVI was measured automatically using VaSera 
VS-1000 (Fukuda Denshi, Tokyo, Japan). Cuffs were 
placed bilaterally on the upper arms and ankles while 
the subjects were lying supine and their heads held in 
midline position. Electrocardiography electrodes were 
placed on both wrists, and a microphone was placed 
to detect heart sounds over the sternum. 
CAVI was determined using the following equa-
tion:
CAVI=a{(2ρ/ΔP)×ln (Ps/Pd) PWV2}＋b,
where a and b are constants, ρ is the blood den-
sity, ΔP is Ps－Pd, Ps is the systolic blood pressure, Pd 
is the diastolic blood pressure, and PWV is the pulse 
wave velocity. 
The actual measurement method of CAVI has 
been previously reported5). In the current study, CAVI 
was measured more than 1 week after admission in a 
stable condition. The average of the right and left 
CAVI values was adopted for analyses.
The brachial-ankle pulse wave velocity (ba PWV) 
was measured using a volume-plethysmography device 
(BP-203RPEII, OMRON COLIN Co., Ltd., Tokyo, 
Japan). The details of the measurements and the 
reproducibility of this automatic method have been 
previously described12). The average of the right and 
left ba PWV values was used for analyses.
Follow-Up
Major adverse outcomes were evaluated for a 
median follow-up of 62 months (interquartile range 
[IQR], 60 to 64 months). The primary endpoint was 
the occurrence of major adverse CV events (MACE), 
defined as CV death, recurrence of ACS, heart failure 
(HF) requiring hospitalization, or stroke. CV death 
was defined as death from acute myocardial infarction, 
HF, stroke, or documented sudden death without 
apparent cardiovascular cause13). Stroke was defined as 
documented focal neurologic deficit and clinically rel-
evant brain imaging of infarction or hemorrhage. The 
most severe endpoint was selected for primary end-
point analysis if ＞1 MACE endpoint occurred during 
follow-up. We defined CV death for the most severe 
endpoint, HF requiring hospitalization for the second, 
stroke for the third and recurrence of ACS was the 
mildest. All events were followed by hospital visits or 
telephone interviews with experienced cardiovascular 
physicians who were not informed of the clinical 
details and results.
Statistical Analysis
Statistical analyses were performed using JMP 
pro 12 (SAS Institute, Inc., Cary, NC) and EZR, 
Kirigaya et al.
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Table 1.  Baseline Clinical and Angiographic Characteristics of Patients with Acute Coronary Syndrome Who 







Male, n (%) 
BMI, kg/m2
Current smoker, n (%) 
Hypertension, n (%) 
Systolic BP at admission, mmHg





Diabetes mellitus, n (%)
HbA1c, % 
History of cerebral infarction, %
History of myocardial infarction, %
Clinical presentation
Unstable angina pectoris, n (%)
ST-segment elevation MI, n (%)
Non-ST-segment elevation MI, n (%)
Culprit artery, n (%) 
Left anterior descending coronary artery
Right coronary artery
Left circumflex coronary artery




In-hospital procedure, n (%)
In-hospital PCI, %
In-hospital CABG, %
hs-CRP at admission, mg/dl





































































































































Values are the mean±standard deviation (SD), n (%), or median (interquartile range) as appropriate. ACEI, angiotensin-con-
verting enzyme-inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CABG, coronary 
artery bypass grafting; CAVI, cardio-ankle vascular stiffness index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglo-
bin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; 
LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous intervention.
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nonfatal stroke. MACE occurred less frequently in the 
low-CAVI group than in the high-CAVI group (7.3% 
vs 23.3%, p＜0.001). The average CAVI values were 
9.0±1.1 in the group with MACE and 8.4±1.2 in 
the group without MACE. CAVI was significantly 
higher in the MACE group than in the without-
MACE group (p＜0.001).
Kaplan–Meier Estimate for Event-Free Rate
Kaplan–Meier curves for patients with high and 
low CAVI values are shown in Fig.3. MACE more 
frequently occurred in patients with high CAVI than 
in those with low CAVI (log-rank, p＜0.001) 
(Fig.3A). CV death also occurred more often in 
patients with high CAVI than in those with low CAVI 
(log-rank, p＜0.001) (Fig.3B).
By multiple adjusted Cox proportional-hazards 
analysis with coronary risk factors and CAVI and ba 
PWV, CAVI could predict MACE (HR, 1.494; 95% 
CI, 1.067–2.120; p=0.021, Model 1 in Table 2) and 
CV death (HR, 2.173; 95% CI, 1.126–4.500; 
p=0.027, Model 1 in Table 3). When adjusted for 
GRS, CAVI was also found to be an independent pre-
dictor of MACE (HR, 1.399; 95% CI, 1.093–1.802; 
p=0.008, Model 2 in Table 2) and CV death (HR, 
2.899; 95% CI, 1.755–5.109; p＜0.001, Model 2 in 
Table 3). In multivariate analysis, although CAVI and 
ba PWV were adopted as variables, both of them are 
index of arterial stiffness and may become a confound-
ing factor. Therefore, we additionally performed a 
multivariate analysis with either ba PWV or CAVI 
were older and had smaller BMI than those in the 
low-CAVI group. There was no significant difference 
in systolic blood pressure at admission between the 
two groups. However, diastolic blood pressure at 
admission was slightly high in the low-CAVI group. 
Hypertension was more prevalent in patients in the 
high-CAVI group than those in the low-CAVI group. 
Current smokers were less frequently observed in the 
low-CAVI group, and lipid profile was better in 
patients with high CAVI than in those with low 
CAVI. Patients in the high-CAVI group had lower 
eGFR at admission and lower left ventricular (LV) 
diastolic function evaluated by E/é than those in the 
low-CAVI group.
ROC Analysis
ROC curves were constructed for the prediction 
of MACE and CV death. ROC analysis for MACE 
demonstrated that CAVI (AUC 0.663: 95% CI, 
0.591–0.729, p＜0.001) was a significant predictor of 
MACE (Fig.2A). ROC analysis for CV death demon-
strated that CAVI (AUC 0.831: 95% CI, 0.715–
0.906, p＜0.001) was a significant predictor of CV 
death (Fig.2B).
Follow-Up and Major Adverse Cardiovascular 
Events
During the median follow-up of 62 months, 62 
patients (16%) experienced MACE: 15 (3.8%) had 
cardiovascular death, 24 (6.3%) had recurrence of 
ACS, 10 (2.5%) had heart failure, and 13 (3.3%) had 
Fig.2. Receiver-operating characteristic (ROC) curves for MACE and cardiovascular (CV) 
death
(A) ROC analysis for MACE demonstrated that CAVI (AUC 0.663. p＜0.001) was significant predic-
tors of MACE. (B) ROC analysis for CV death demonstrated that CAVI (AUC 0.831. p＜0.001) was 
significant predictors of CV death. AUC, area under the curve; CAVI, cardio-ankle vascular stiffness 
index; MACE, major adverse cardiovascular events; CV, cardiovascular. 
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p=0.051, Model 3 in Supplementary Table 1). In 
multivariate analysis of CV death without ba PWV, 
CAVI was an independent predictor of CV death after 
adjustment for coronary risk factors (HR, 2.309; 95% 
CI, 1.273–4.487; p=0.008, Model 1 in Supplemen-
tary Table 2). However, ba PWV was not a significant 
predictor of CV death in multivariate analysis without 
CAVI (HR, 1.001; 95% CI, 0.999–1.003; p=0.109, 
Mode 2 in Supplementary Table 2). When adjusted 
for GRACE risk score, ba PWV was an independent 
predictor of CV death (HR, 1.002; 95% CI, 1.000–
separately. When we performed multivariate analysis 
of MACE without ba PWV, CAVI was a significant 
predictor of MACE after adjustment for the tradi-
tional coronary risk factors (HR, 1.549; 95% CI, 
1.149–2.109; p=0.004, Model 1 in Supplementary 
Table 1). Although there was a similar trend for ba 
PWV, it did not reach statistical significance (HR, 
1.000; 95% CI, 0.990–1.001; p=0.082, Model 2 in 
Supplementary Table 1). When adjusted for GRACE 
risk score, ba PWV was also not an independent pre-
dictor of MACE (HR, 1.000; 95% CI, 0.999–1.001; 
Table 2. Univariate and multivariate logistic regression analysis-estimate hazard ratio for major adverse cardiovascular events
Variable Univariate Multivariate (Model 1) Multivariate (Model 2)
HR 95% CI p value HR 95% CI p value HR 95% CI p value






BMI, per 1 kg/m2






































































































ba PWV, brachial-ankle pulse wave velocity; BMI, body mass index; eGFR, estimated glomerular filtration rate; GRACE, global registry of acute 
coronary events; HR, hazard ratio; 95% CI, 95% confidence interval.
Fig.3. Kaplan-Meier estimates for major adverse events according to CAVI
Kaplan-Meier estimates are shown for the rate of major adverse cardiovascular events (CV death, recurrence of ACS, heart 
failure requiring hospitalization or stroke) (A) and CV death (a death from acute myocardial infarction, heart failure, stroke, 
or documented sudden death without apparent non-cardiovascular cause) (B) according to CAVI. CAVI, cardio-ankle vas-
cular index; ACS, acute coronary syndrome. 
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0.034), suggesting an effective reclassification. The 
integrated discrimination improvement (IDI) again 
showed that the diagnostic performance of the model 
was significantly improved by adding CAVI to the 
GRS (IDI: 0.028, p=0.004). For the sensitivity analy-
sis, CAVI, comparing to GRS, was more strongly and 
gradually associated with MACE, in which the odds 
ratios (95% CIs) of higher GRS and lower CAVI, 
lower GRS and higher CAVI, and higher GRS and 
higher CAVI against lower GRS and lower CAVI were 
1.238 (0.359–3.891), 3.076 (1.246–8.088), and 4.816 
(2.232–11.621), respectively.
1.003; p＜0.001, Model 3 in Supplementary Table 
2).
CAVI and GRACE Risk Score
We evaluated the incremental effect of adding 
CAVI to the GRS for predicting MACE. When we 
divided all patients into four groups according to the 
cut-offs for CAVI and GRS ＞140, significantly 
higher MACE rates were seen in patients with both 
higher CAVI and higher GRS (n=35, 26.1% of all 
patients) than the other groups (p＜000.1) (Fig.4). 
Furthermore, the inclusion of CAVI into the GRS 
model was associated with an NRI of 33.7% (p=  
Table 3. Univariate and multivariate logistic regression analysis-estimate hazard ratio for cardiovascular death
Variable Univariate Multivariate (Model 1) Multivariate (Model 2)
HR 95% CI p value HR 95% CI p value HR 95% CI p value






BMI, per 1 kg/m2











































































ba PWV, brachial-ankle pulse wave velocity; BMI, body mass index; eGFR, estimated glomerular filtration rate; GRACE, global registry of acute 
coronary events; HR, hazard ratio; 95% CI, 95% confidence interval.
Fig.4. Relation of high or low CAVI and GRACE risk score
When we divided all patients into four groups according to the cut-offs for CAVI and GRACE risk 
score ＞140, significantly higher MACE rates were seen in patients with both higher CAVI and higher 
GRACE risk score (n=35, 26.1% of all patients) than the other groups (p＜000.1). CAVI, cardio-ankle 




ness induced higher LV filling pressure and diastolic 
dysfunction19). A number of studies demonstrated that 
diastolic dysfunction was associated with a poor prog-
nosis in patients with ACS20, 21). In our study, E/é, 
which was previously shown to be an indicator of LV 
diastolic dysfunction22), was significantly elevated in 
the high-CAVI group as compared to that in the low-
CAVI group.
Comparison with Previous Studies
Previous studies investigated the effect of arterial 
stiffness on CV outcomes in patients with ACS. Tomi-
yama et al. reported that ba PWV was an independent 
predictor of the prognosis of patients with ACS23). In 
our study, there was a significant relationship between 
ba PWV and major adverse events in the univariate 
analysis but not in the multivariate analysis that 
included CAVI. In addition, when we performed mul-
tivariate analysis of major adverse events without ba 
PWV, CAVI was a significant predictor of MACE 
after adjustment for the established coronary risk fac-
tors. Although there was a similar trend for ba PWV, 
it did not reach statistical significance. These findings 
may be related to some as-yet undetermined effects on 
blood pressure at the time of the examination or the 
superiority of CAVI over ba PWV as a method of 
measuring arterial stiffness24). 
Hans-Josef et al. reported that aortic PWV mea-
sured by cardiac magnetic resonance imaging (MRI) 
was an independent predictor of MACE comprising 
all-cause death, nonfatal myocardial reinfarctions, new 
congestive heart failure, and strokes4). Another study 
found that phase-contrast cardiac MRI could provide 
an accurate and reproducible method for the determi-
nation of PWV25). However, aortic stiffness measured 
by cardiac MRI requires more time and complex cal-
culations. In addition, it can be performed in specific 
situations. Therefore, cardiac MRI is not suitable for 
all types of acutely hospitalized patients with ACS. 
However, CAVI can easily be measured in the clinical 
setting. Thus, we think that CAVI is a more useful 
predictive tool than cardiac MRI for all types of ACS. 
As noted earlier, previous studies revealed the sig-
nificance of arterial stiffness in the prognosis of 
patients with ACS. However, no previous studies 
examined the association between arterial stiffness and 
CV mortality in patients with ACS. Moreover, other 
previous studies were based on smaller study popula-
tions and shorter follow-up duration than ours. Fur-
thermore, critically ill patients, such as those with HF 
or CKD, were excluded in the previous studies. In the 
current study, we could explore the role of arterial 
stiffness in such seriously ill patients using CAVI, 
which is an easy and noninvasive measurement of 
Discussion
The main finding of the current study was that 
arterial stiffness assessed using CAVI was a significant 
and independent predictor of long-term incidence of 
MACE, especially CV death in patients with ACS. 
Furthermore, the results demonstrated that the prog-
nostic performance of CAVI was independent of the 
GRS and the addition of CAVI to the GRS improved 
risk stratification in ACS patients. To the best of our 
knowledge, this is the first study to reveal the role of 
arterial stiffness evaluated using CAVI in long-term 
incidence of MACE and CV death in patients with 
ACS.
The Role of CAVI in the Prognosis
Previously, some studies reported that arterial 
stiffness was a significant predictor of adverse events 
in patients with coronary artery disease3, 4, 15, 16). How-
ever, the prognostic role of this parameter in patients 
with ACS has not been fully understood. In the cur-
rent study, we demonstrated the independent predic-
tive value of CAVI after adjustment for classic CV risk 
factors. In addition, the combined use of CAVI and 
GRS improved risk stratification in patients with 
ACS. These results suggested that CAVI has an 
adjunctive value in the assessment of traditional CV 
risk factors. This may be because CAVI reflects dam-
age in the arterial wall over a long period. By contrast, 
blood pressure, glycemia, and lipids cannot reflect the 
genuine damage on the arterial wall because their val-
ues may fluctuate depending on the timing15). There-
fore, we think that CAVI can serve as an additional 
prognostic tool to stratify patients with ACS at risk of 
the development of events, beyond the assessment of 
traditional atherosclerotic risk factors. 
Organ damage caused by increased arterial stiff-
ness may worsen the prognosis of patients with ACS. 
Previous studies showed that increased arterial stiffness 
determined using CAVI was associated with athero-
sclerotic diseases such as cerebral infarctions and 
chronic kidney disease (CKD)3, 17). In the current 
study, more patients with a high CAVI had a history 
of cerebral infarctions and renal insufficiency as com-
pared with patients with a low CAVI. Previous studies 
revealed that cerebral infarctions and CKD were pre-
dictors of CV events in ACS8, 18). Hence, in the cur-
rent study, atherosclerotic organ damage induced by 
increased arterial stiffness may adversely affect the 
prognosis of patients with ACS. 
In addition, LV diastolic dysfunction induced by 
increased arterial stiffness may worsen the prognosis of 
patients with ACS. Previous studies reported that an 
increased LV afterload caused by elevated arterial stiff-
CAVI for Acute Coronary Syndrome
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risk factor of recurrent atherosclerotic events, was less 
observed in the high-CAVI group than in the low-
CAVI group. The relationship between CAVI and dys-
lipidemia has not been consistent with past studies30, 31). 
The higher proportion of elderly people in the high-
CAVI group may affect the lipid profile32). Forth, 
compared to other recent studies, the rate of major 
adverse events in our study was relatively low2, 18). This 
better outcome may be explained by the extremely 
high proportion of patients who underwent 
percutaneous coronary intervention (92.1%) or coro-
nary artery bypass grafting (4.8%). 
Conclusion
Arterial stiffness determined using CAVI was an 
independent long-term predictor of MACE in patients 
with ACS. Furthermore, we demonstrated that the 
additional usefulness of CAVI can improve risk strati-
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CAVI as a marker of arterial stiffness is most reliable 
and reproductive in the current era. 
Clinical Implications
The GRS is widely used, simple to assess, and 
effective in risk estimation of mortality and is recom-
mended for all types of patients with ACS8). However, 
this score, which is based on common traditional risk 
factors for CV disease, was derived in the early 21st 
century. Since that time, many novel risk factors, 
including arterial stiffness, have been studied. The 
GRS does not include any of these new risk factors. 
Our study was the first to demonstrate that the addi-
tion of CAVI could improve risk stratification based 
on the GRS.
CAVI, which is not influenced by blood pressure 
at the time of the examination, integrates measure-
ments of CV risk factors such as aging, hypertension, 
diabetes mellitus, and dyslipidemia5, 15). Therefore, it 
is reasonable that CAVI has better predicted values 
than each of these classic risk factors and shows the 
added value to GRS.
Otsuka et al. reported that persistent impairment 
of arterial stiffness assessed using CAVI was associated 
with future CV events, even after comprehensive man-
agement of traditional atherosclerotic risk factors in 
patients with stable coronary artery disease26). This 
suggested that serial assessments of arterial stiffness 
using CAVI could serve as an indicator of the need for 
treatment. Moreover, several interventional studies 
showed that nonpharmacological and pharmacological 
treatments were associated with an improvement in 
CAVI27-29). To determine the utility of CAVI in 
patients with ACS, more clinical and experimental 
studies are required. In addition, a therapeutic strategy 
for improving arterial stiffness in ACS needs to be 
developed.
Limitations
This study has limitations that need to be 
acknowledged. First, this study was based on a rela-
tively small sample size at a single center. However, in 
comparison with previous studies, our study included 
the largest number of patients and had a longer fol-
low-up duration so that we could clearly reveal the 
significance of arterial stiffness measured by CAVI. 
Second, we excluded patients with severe aortic insuf-
ficiency, peripheral artery disease, and persistent atrial 
fibrillation because it was difficult to accurately mea-
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dyslipidemia, which is thought to be a conventional 
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Supplementary Table 1.  Univariate and multivariate logistic regression analysis-estimate hazard ratio for major adverse cardiovas-
cular events
Variable Multivariate (Model 1) Multivariate (Model 2) Multivariate (Model 3)
HR 95% CI P value HR 95% CI P value HR 95% CI P value






BMI, per 1 kg/m2
































































Model 1 age, male, current smoker, hypertension, dyslipidemia, diabetes mellitus, BMI, eGFR and CAVI, Model 2 age, male, current smoker, 
hypertension, dyslipidemia, diabetes mellitus, BMI, eGFR and ba PWV, Model 3 GRACE risk score and ba PWV. GRACE, global registry of acute 
coronary events; HR, hazard ratio; 95% CI, 95% confidence interval; Other abbreviations as in Table 1
Supplementary Table 2. Univariate and multivariate logistic regression analysis-estimate hazard ratio for cardiovascular death
Variable Multivariate (Model 1) Multivariate (Model 2) Multivariate (Model 3)
HR 95% CI p value HR 95% CI p value HR 95% CI p value






BMI, per 1 kg/m2







































































BMI, body mass index; eGFR, estimated glomerular filtration rate; ba PWV, brachial-ankle pulse wave velocity; GRACE, global registry of acute 
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